Abstract:
Thiazole or thiadizaloe derivatives of formula (I) or pharmaceutical salts thereof having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptor are disclosed.
Abstract:
The invention is directed to novel indole carboxamide compounds. Specifically, the invention is directed to compounds according to formula (I): wherein R1, R2, R3, R4, and m are as defined herein.The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, rhinitis, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
Abstract:
The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.
Abstract:
Novel substituted 1,5,7-trisubstituted-1,8-napthyridin-2(1H)-one compounds; 1,5,7 trisubstituted-1,6-napthyridine-2-(1H)-one compounds and 1,5,7-trisubstituted quinoline-2(1H)-one compounds, processes for the preparation thereof, the use thereof in treating CSBP/p38 kinase mediated diseases and pharmaceutical compositions for use in such therapy.
Abstract:
The present invention is directed to a novel method of preparing of 2,4,8-trisubstituted pyrido[2,3-d]pyrimidin-7-one pharmacophores of Formula (II) or (IIa) wherein G1 is CH2; G2 is CH; Rx is chloro, bromo, iodo, or O—S(O)2CF3; Rg is a C1-10 alkyl; m is 0, or an integer having a value of 1, or 2; R3 is a C1-10 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-10 alkyl, aryl, arylC1-10 alkyl, heteroaryl, heteroarylC1-10 alkyl, heterocyclic or a heterocyclylC1-10 alkyl moiety, and wherein each of these moieties may be optionally substituted. which comprises reacting a compound of the formula: wherein Ry is chloro, bromo, iodo, O—S(O)2CF3; and Rg is a C1-10 alkyl; with a olefin forming reagent in a suitable base to yield a compound of Formula (II), or (IIa) wherein m=0 and oxidizing the sulphur as necessary or desired.
Abstract translation:本发明涉及制备式(II)或(IIa)的2,4,8-三取代吡啶并[2,3-d]嘧啶-7-酮药代动力学的新方法,其中G1是CH2; G2是CH; R x是氯,溴,碘或O-S(O)2 C 3 F 3; Rg为C1-10烷基; m为0,或值为1或2的整数; R 3是C 1-10烷基,C 3-7环烷基,C 3-7环烷基C 1-10烷基,芳基,芳基C 1-10烷基,杂芳基,杂芳基C 1-10烷基,杂环基或杂环基C 1-10烷基部分,并且其中 部分可以任选被取代。 其包括使下式化合物:其中R y是氯,溴,碘,O-S(O)2 C 3 F 3; 且R g为C 1-10烷基; 在合适的碱中加入烯烃形成试剂,得到式(II)化合物或其中m = 0的(IIa),并根据需要氧化硫。
Abstract:
The present invention is directed to a novel method of preparing of 2,4,8-trisubstituted pyrido[2,3-d]pyrimidin-7-one pharmacophores of Formula (II) or (IIa) wherein G1 is CH2 or NH: G2 is CH or nitrogen; Rx is chloro, bromo, iodo, or O—S(O)2CF3; Rg is a C1-10alkyl; m is 0, or an integer having a value of 1, or 2; R3 is a C1-10 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-10 alkyl, aryl, arylC1-10 alkyl, heteroaryl, heteroarylC1-10 alkyl, heterocyclic or a heterocyclylC1-10 alkyl moiety, and wherein each of these moieties may be optionally substituted. which comprises reacting a compound of the formula: wherein Ry is chloro, bromo, iodo, O—S(O)2CF3; and Rg is a C1-10 alkyl; with a olefin forming reagent in a suitable base to yield a compound of Formula (II), or (IIa) wherein m=0 and oxidizing the sulphur as necessary or desired.
Abstract translation:本发明涉及一种制备式(II)或(IIa)的2,4,8-三取代吡啶并[2,3-d]嘧啶-7-酮药效团的新方法,其中G1是CH2或NH:G2 是CH或氮; R x是氯,溴,碘或O-S(O)2 C 3 F 3; Rg为C1-10烷基; m为0,或值为1或2的整数; R 3是C 1-10烷基,C 3-7环烷基,C 3-7环烷基C 1-10烷基,芳基,芳基C 1-10烷基,杂芳基,杂芳基C 1-10烷基,杂环基或杂环基C 1-10烷基部分,并且其中 部分可以任选被取代。 其包括使下式化合物:其中R y是氯,溴,碘,O-S(O)2 C 3 F 3; 且R g为C 1-10烷基; 在合适的碱中加入烯烃形成试剂,得到式(II)化合物或其中m = 0的(IIa),并根据需要氧化硫。
Abstract:
Novel substituted 1,5,7-trisubstituted-1,8-napthyridin-2(1H)-one compounds; 1,5,7 trisubstituted-1,6-napthyridine-2-(1H)-one compounds and 1,5,7-trisubstituted quinoline-2(1H)-one compounds, processes for the preparation thereof, the use thereof in treating CSBP/p38 kinase mediated diseases and pharmaceutical compositions for use in such therapy.